From 24/7 Wall St. · Trey Thoelcke · · 1m 10s
Viking Soars Alone as Obesity Complex Shrugs
Viking Therapeutics jumps 26.5% after GLP-1 results while obesity peers barely move.
In brief
Viking Therapeutics jumps 26.5% after GLP-1 results while obesity peers barely move. Viking Therapeutics surged 26.5% on strong GLP-1 maintenance data as obesity peers showed minimal reaction. Originally reported by 24/7 Wall St..
Viking Therapeutics Surges
Viking Therapeutics traded at $38.08, a session gain of 26.5% on September 22, 2026, after releasing positive GLP-1 maintenance results.
“Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse”
Obesity Peers Barely Moved
Structure Therapeutics fell 0.7% extending a 47.4% year-to-date decline while Eli Lilly and Novo Nordisk showed minimal price action.
“Structure traded at $36.56, down 0.7% on the session, extending a 47.4% year-to-date decline”
GLP-1 Maintenance Study
Viking reported a randomized trial showing weekly induction dosing followed by monthly or every-other-week maintenance regimens.
“The company framed the data as validating multiple maintenance schedules, a commercially significant finding because patient adherence is a well-known weakness of injectable GLP-1s”
Prior Phase 2 Results
Previous trials showed up to 14.7% body weight reduction after 13 weekly doses with 80% of subjects reaching at least 10% weight loss.
“VENTURE showed up to 14.7% mean body weight reduction after 13 weekly subcutaneous doses; VENTURE-Oral delivered up to 12.2% at 13 weeks”
Obesity Complex Reaction
Eli Lilly added 1.1% to $1,177.43 while Novo Nordisk slipped 0.7% to $39.54 amid list-price cuts effective January 2027.
“Novo Nordisk slipped 0.7% to $39.54, deepening a 32.5% one-year decline as the company works through list-price cuts of about 50% for Wegovy and 35% for Ozempic effective January 1, 2027”
Buyout Case Strengthens
Viking’s strong data hardens its standalone position with $502 million cash and fully enrolled Phase 3 trials.
“Strong data cuts both ways. It hardens Viking’s standalone posture, which already includes $502 million in cash at quarter end and both VANQUISH-1 and VANQUISH-2 fully enrolled”
Next Steps for Viking
Oral VK2735 Phase 3 trials expected in Q4 2026 with 78-week VANQUISH results to follow.
“Lian has said oral VK2735 Phase 3 initiation is expected in Q4 2026, positioning it to potentially become the first orally available dual GLP-1/GIP agonist to reach market”
The key point
Viking Therapeutics surged 26.5% on strong GLP-1 maintenance data as obesity peers showed minimal reaction.
